CD200 Antibody

What is CD200 and what is its role in immune regulation?

CD200 is a cell surface glycoprotein belonging to the immunoglobulin superfamily that exerts immunosuppressive signaling through its receptor CD200R, which is present on immune cells . CD200 is expressed by a subset of B lymphocytes, some endothelial cells, and neurons . The CD200-CD200R system plays a crucial role in the control of macrophage and granulocyte activation . When CD200 binds to CD200R on myeloid cells, it delivers inhibitory signals that suppress immune cell functions, including cytokine production and effector responses . In experimental models lacking CD200, animals display increased susceptibility to autoimmunity and earlier onset of aggressive autoimmune disease, demonstrating the importance of this pathway in maintaining immune homeostasis .

Which cell types express CD200 and CD200R in normal and pathological conditions?

In normal conditions, CD200 expression is observed on a subset of B lymphocytes, certain endothelial cells, and neurons . CD200R is predominantly expressed on myeloid lineage cells, including macrophages, neutrophils, and dendritic cells, as well as on some lymphoid populations . In pathological conditions such as acute myeloid leukemia (AML), CD200 is overexpressed in approximately 40% of patients and is particularly enriched in leukemic stem cells (LSCs) . This overexpression has been associated with poor prognosis in AML patients . In multiple myeloma, CD200 is overexpressed on aberrant plasma cells and serves as an independent negative prognostic factor for survival . CD200R expression can be detected on cytotoxic immune cell populations, including on CD56+CD3+ and CD56-CD3+ cytokine-induced killer (CIK) cells .

How does CD200 expression correlate with clinical outcomes in hematological malignancies?

Research has demonstrated that CD200 expression is associated with inferior clinical outcomes in several hematological malignancies. In AML, high CD200 expression correlates with poor prognosis compared to CD200 low/negative patients . Studies have shown that CD200 High AML patients exhibited reduced Natural Killer (NK) and T cell immune responses compared to CD200 Low patients, suggesting that CD200 contributes to immune evasion and therapy relapse . CD200 has been identified as a potential marker for leukemic stem cells responsible for relapse in AML . Similarly, in multiple myeloma, CD200 overexpression on aberrant plasma cells is an independent negative prognostic factor for survival . These correlations underscore the potential value of targeting CD200 as a therapeutic strategy in hematological malignancies.

What are the optimal conditions for using anti-CD200 antibodies in experimental settings?

When using anti-CD200 antibodies in research settings, several factors should be considered for optimal results. For immunohistology of frozen samples and flow cytometry applications, a Mouse Anti-Human CD200 antibody with an IgG concentration of 1.0mg/ml has been validated . The antibody should be stored at -20°C to maintain stability and efficacy . For blocking experiments using anti-CD200 antibodies such as TTI-CD200, the optimal blocking concentration should be determined empirically for each experimental system . When using anti-CD200 antibodies in in vivo experiments, administration protocols that have shown efficacy include injecting the antibody every two days following engraftment of target cells . For long-term studies, it's important to maintain consistent antibody dosing schedules to ensure continuous blocking of CD200-CD200R interactions throughout the experimental period.

How can researchers effectively evaluate the functional effects of CD200 blockade?

Researchers can evaluate the functional effects of CD200 blockade through several validated approaches. Cell-based assays can be used to determine the neutralizing potency of anti-CD200 antibodies against human CD200 with nanomolar precision . To assess the impact on immune effector functions, researchers can measure:

• CD107a expression on effector cells (e.g., NK cells, T cells) as a marker of degranulation following co-culture with CD200+ targets in the presence of anti-CD200 antibodies or isotype controls .

• Cytokine production, particularly IFN-γ release, using ELISPOT assays when comparing anti-CD200 treatment versus isotype control in CD200 High versus CD200 Low target cells .

• Cytotoxicity assays at different effector:target ratios to evaluate the enhancement of immune cell-mediated killing following CD200 blockade .

• In vivo engraftment studies using humanized mouse models to assess the impact of anti-CD200 treatment on disease progression and immune cell infiltration .

These methodological approaches provide complementary data to comprehensively evaluate how CD200 blockade affects immune responses against CD200-expressing targets.

What experimental models are most suitable for studying CD200-CD200R interactions?

Several experimental models have proven valuable for studying CD200-CD200R interactions:

For studying the role of CD200 in cancer, isogenic cell line models with controlled CD200 expression (such as K562-CD200+ versus K562-CD200- cells) provide a clean system to characterize CD200-mediated immunosuppression on various immune cell subsets both in vitro and in vivo . For autoimmunity research, experimental autoimmune uveoretinitis (EAU) has been used effectively as a model to study CD200-CD200R interactions, particularly in tissues with extensive neuronal and endothelial CD200 expression . PBMC-humanized mouse models are particularly valuable for translational studies, allowing assessment of how CD200+ leukemia evades elimination by T cells compared to CD200- leukemia .

How does CD200 expression on cancer cells modulate immune cell metabolism and function?

Recent research has uncovered a novel mechanism by which CD200 expression on cancer cells impairs immune cell metabolism and function. Studies have shown that CD200 expression on AML cells significantly impairs oxidative phosphorylation (OXPHOS) metabolic activity in T cells from healthy donors . This metabolic impairment appears to be a key mechanism underlying CD200-mediated immunosuppression. In a PBMC-humanized mouse model, T cells from mice with CD200+ AML were characterized by an abundance of metabolically quiescent CD8+ central and effector memory cells .

The metabolic reprogramming induced by CD200-CD200R interaction affects multiple aspects of immune cell function, including:

• Reduced cytokine secretion in both innate and adaptive immune cell subsets

• Impaired proliferative capacity of effector cells

• Decreased cytotoxic potential against CD200-expressing targets

• Altered memory T cell differentiation and function

These findings indicate that CD200 overexpression represents a stem cell-specific mechanism of immune evasion that contributes to immunosuppression by impairing effector cell metabolism and function . This understanding opens new avenues for therapeutic interventions that could target both the CD200-CD200R interaction and the metabolic consequences of this signaling pathway.

What strategies can overcome CD200-mediated immunosuppression in cancer immunotherapy?

Several promising strategies have been developed to overcome CD200-mediated immunosuppression in cancer immunotherapy:

• Blocking antibodies: Fully human anti-CD200 antibodies (e.g., TTI-CD200) that block the interaction between CD200 and CD200R have shown efficacy in restoring immune responses against AML both in vitro and in vivo . These antibodies can enhance the function of autologous immune cells ex vivo and significantly improve the efficacy of adoptive immune effector cells towards residual cancer cells in vivo .

• Genetic engineering approaches: For adoptive cell therapies like CAR T cells, several genetic modifications have been tested to overcome CD200-mediated suppression:

  • CRISPR-Cas9-mediated knockout of CD200R (CD200RKO)

  • Expression of dominant-negative CD200R (CD200RDN)

  • Development of CD200R-CD28 switch receptors that convert inhibitory signals into costimulatory ones

  Among these approaches, the CD200R-CD28 switch has shown the most promise, potently enhancing CAR T-cell polyfunctionality, cytotoxicity, proliferative capacity, and metabolism .

• Combination therapies: CD200 antibody therapy has shown synergistic effects when combined with other treatment approaches. For example, CD200 antibody therapy significantly improved the efficacy of low-intensity azacitidine/venetoclax chemotherapy in immunodeficient hosts with AML .

These strategies represent promising approaches to target the CD200-CD200R axis in cancer immunotherapy, with potential applications in both hematological malignancies and solid tumors expressing CD200.

How do agonistic versus antagonistic anti-CD200R antibodies differ in their immune modulation?

Agonistic and antagonistic anti-CD200R antibodies exert opposite effects on immune responses through distinct mechanisms:

Agonistic anti-CD200R antibodies:

• Deliver negative signals to immune cells such as bone marrow-derived macrophages

• Suppress interferon (IFN)γ-mediated nitric oxide (NO) and interleukin-6 production

• Can prevent full expression of IFNγ-mediated macrophage activation

• Have shown therapeutic potential in models of autoimmunity by maintaining tonic suppression of macrophage activation

• In experimental autoimmune uveoretinitis (EAU), systemically administered agonistic antibodies suppressed disease despite maintained T-cell proliferation and IFNγ production

• Local administration resulted in earlier resolution of autoimmune disease

Antagonistic (blocking) anti-CD200R antibodies:

• Block the interaction between CD200 and CD200R

• Prevent delivery of inhibitory signals to immune cells

• Enhance immune cell functions including cytokine production and cytotoxicity

• Restore impaired immune responses against CD200-expressing cancer cells

• Can significantly improve the efficacy of adoptive cellular therapies

• May induce Fc-mediated immune responses when designed with appropriate Fc regions

The choice between agonistic and antagonistic approaches depends on the therapeutic context: antagonistic antibodies are preferred for cancer immunotherapy to enhance anti-tumor immunity, while agonistic antibodies may be beneficial in autoimmune conditions to suppress pathological immune activation.

What is the impact of CD200 expression on CAR T-cell therapy in multiple myeloma?

CD200 expression on aberrant plasma cells in multiple myeloma has significant implications for CAR T-cell therapy outcomes:

• The levels of CD200 expressed by aberrant plasma cells in multiple myeloma are sufficient to inhibit the activity of clinically relevant CAR T cells, including those targeting B-cell maturation antigen (BCMA) or the Tn glycoform of mucin 1 (TnMUC1) .

• This inhibition likely contributes to the common pattern observed in multiple myeloma patients treated with BCMA-specific CAR T cells, who usually relapse with BCMA+ disease, indicative of CAR T-cell suppression rather than antigen loss .

• Different approaches to overcome CD200-mediated suppression of CAR T cells show varying efficacy:

  • Surprisingly, CRISPR-Cas9-mediated knockout of CD200R (CD200RKO) was detrimental to CAR T-cell activity, adversely affecting CAR T-cell metabolism

  • Expression of dominant-negative CD200R (CD200RDN) provided modest benefits

  • The CD200R-CD28 switch receptor showed the most promise, potently enhancing CAR T-cell polyfunctionality, cytotoxicity, proliferative capacity, and metabolism

• These patterns were consistent across in vitro assays and in vivo models, including murine xenograft models of plasmacytoma and disseminated bone marrow predominant disease .

These findings underscore the importance of addressing CD200-mediated immune suppression in CAR T-cell therapy for multiple myeloma and highlight the CD200R-CD28 switch as a promising approach to enhance such therapies by leveraging CD200 expression on aberrant plasma cells to provide costimulation.